Contrary Research

Startup Search

Contrary is a talent and research-driven investment firm. We back a small number of exceptional people and the companies they build, from seed to scale.

Ninja Delivery

Contrary

We’re thrilled to co-lead Power's $12M Series A, alongside our friends Nikhil Basu Trivedi at Footwork and Kin Ventures.

Patient recruitment is a massive bottleneck in clinical trials. 86% of U.S. trials are delayed due to lack of enrollment. Yet <5% of American patients participate in potentially life-changing trials. Many must advocate for themselves, wrestling with dense jargon, unclear tradeoffs, and an opaque enrollment process.

Power is reimagining trial recruitment starting with a patient-led marketplace. Therapeutic options should be easily accessible for everyone — regardless of geographical location, ethnicity, or socioeconomic background.

Unlocking access for patients is only act one. We believe Power has the potential to redefine how patients, researchers, and life science partners interact in the clinical trial system.

Congratulations to Charles Wu and the entire Orchard team on their seed round led by General Catalyst!

We’re thrilled to have led their pre-seed and to continue supporting them on their journey to enable the next generation of precision crop management and farm technology.

https://lnkd.in/ecpedV2z

For a long time, scientists had to rely on imperfect and limited methods of observation to build an understanding of biology. 

This all changed with the discovery of CRISPR technologies in 2012, which granted researchers an unprecedented degree of control over genetic material. 

For the first time, it was possible to not only observe biology but to alter and even design it. 

This new set of tools and abilities has unlocked tremendous opportunity, with untold applications within the realms of therapeutics, industry, and research. 

In just a few short years, CRISPR has moved the field of biology outside of the realm of mere observation and analysis and placed it squarely within the domain of engineering.

In the latest essay for Foundations & Frontiers, Anna-Sofia Lesiv dives into the workings, origins, and implications of gene editing. 

Ramp is joining our SF Tech Talk on May 22nd!

Meet them and other eng leaders from Hex, Sourcegraph, Semgrep, Onehouse, Weaviate as they demo their latest features for top builders in the Bay.

Sign up here: https://lu.ma/sftechtalk2

Last SF Tech Talk had over 400 signups. We’re thrilled to be hosting our next Tech Talk in SF with senior engineers and PMs from Hex, Sourcegraph, Semgrep, Onehouse, and Weaviate.

An evening built by engineers for engineers — each company will live demo their latest product features for leading builders in the Bay.

Sign up here: https://lu.ma/sftechtalk2

Contrary is a technology company that leverages data science to identify and invest in emerging talent and startups. It operates a platform that combines machine learning with a global network of scouts to discover and support entrepreneurs and innovators.

COM:CONTRARY

Contrary

Filings Not Available